(Photo by Flickr user Luca Volpi, used under a Creative Commons license)
After six years of existence and raising more than $20 million, Personal Genome Diagnostics has its first full-time CEO.
Douglas Ward will head the Canton-based Johns Hopkins spinout and sit on its board, the company announced Monday.
Ward has worked in medical diagnostics for 25 years, most recently serving as Vice President of Companion Diagnostics at Ventana Medical Systems. He has also worked at GE Healthcare and Bayer Healthcare.
Founded in 2010 by Hopkins cancer researchers Victor Velculescu and Luis Diaz, Personal Genome Diagnostics specializes in technology to assist cancer genome testing. The company closed a $21.4 million Series A led be NEA in 2015.
Personal Genome Diagnostics previously did not have a CEO. A spokeswoman said Ward is “expected to build on the company’s record of strong growth and provide experienced leadership for the further development of key product lines.”
This Week in Jobs: Now in Euros
Power Moves: Leadership changes at CAMI and Maryland Momentum Fund
This Week in Jobs: Take an innovacation
What Asymmetrik is doing to help lead healthcare’s digital transformation
Say no to FOMO: Super Meetup is today at R. House
BurnAlong adds digital connection to the local American Heart Association’s CycleNation event
This Week in Jobs: Peace and Love Edition
Verizon is looking for the brightest ideas on how to use its 5G technology
Sign-up for daily news updates from Technical.ly Baltimore